EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieOpen access · CC BY-NC-ND 4.0

ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2

Robyn H Guymer, Rufino Silva, Mercedeh Ghadessi, Sergio Leal, Isabella Gashaw, Amy Damask, Charles Paulding, Kay D Rittenhouse

Investigative Ophthalmology & Visual Science · 2024

DOI: 10.1167/iovs.65.8.17 ↗

At a glance

Randomisierte kontrollierte Studie in Investigative Ophthalmology & Visual Science, 2024. Written by Robyn H Guymer and 7 co-authors. Institution: Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia. Major MEDLINE topics: Intravitreal Injections, Angiogenesis Inhibitors, Visual Acuity, Vascular Endothelial Growth Factor A. Cited 6 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

This analysis investigated potential associations between gene variants and clinical end points in the VIEW 1 and 2 randomized clinical trials of intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration (AMD).

Methods

A genome-wide association analysis was conducted in a subgroup of patients from VIEW 1 and 2 consenting to the optional pharmacogenetic analysis.

Results

Data were pooled from 780 samples from patients representative of the overall VIEW 1 and 2 populations. After Bonferroni correction for multiplicity and statistical adjustment for baseline risk factors, no significant associations were found between previously identified prognostic AMD gene variants and treatment response according to key prespecified VIEW 1 and 2 end points. Genome-wide, there were no significant genetic associations in patients experiencing gains of ≥15 Early Treatment of Diabetic Retinopathy Study letters after 1 or 2 years of treatment. A cluster of variants in ANO2 (encoding anoctamin 2, a calcium-activated chloride channel expressed on photoreceptor cells) on chromosome 12 reached the level of significance for loss of ≥5 letters after 1 year of treatment (P < 5 × 10-8), with the ANO2 rs2110166 SNP demonstrating highly significant association (P = 1.99 × 10-8). Carriers of the ANO2 rs2110166 TT genotype showed a robust increase in visual acuity versus baseline compared with a small decrease in those with the TC genotype.

Conclusions

None of the potential prognostic candidate genes were associated with the clinical end points for treated patients. Preliminary analyses suggest an association of ANO2 with retinal function, with a potential impact on vision of approximately one line over at least the first year. Further investigation of the function of ANO2 in retinal pathophysiology is merited.

Subjects

MeSH terms (MEDLINE)

Intravitreal InjectionsAngiogenesis InhibitorsVisual AcuityVascular Endothelial Growth Factor ARanibizumabRecombinant Fusion ProteinsGenome-Wide Association StudyPolymorphism, Single NucleotideReceptors, Vascular Endothelial Growth FactorAnoctaminsHumansMaleFemaleAgedWet Macular DegenerationAged, 80 and overGenotypeTreatment OutcomePharmacogeneticsPharmacogenomic Testing

Substances

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorafliberceptAnoctaminsVEGFA protein, human

Authors and institutions

  • Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
  • The University of Melbourne, Melbourne, Australia.
  • Faculty of Medicine, University of Coimbra (FMUC-UC), Coimbra, Portugal.
  • Unidade Local de Saude de Coimbra (ULS-Coimbra), Coimbra, Portugal.
  • Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal.
  • Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal.

Cite

APA

Guymer, R. H., Silva, R., Ghadessi, M., Leal, S., Gashaw, I., Damask, A., Paulding, C., & Rittenhouse, K. D. (2024). ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.65.8.17

Vancouver

Guymer RH, Silva R, Ghadessi M, Leal S, Gashaw I, Damask A, et al. ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2. Investigative Ophthalmology & Visual Science. 2024. doi:10.1167/iovs.65.8.17

BibTeX
@article{Guymer2024,
  author = {Guymer, Robyn H and Silva, Rufino and Ghadessi, Mercedeh and Leal, Sergio and Gashaw, Isabella and Damask, Amy and Paulding, Charles and Rittenhouse, Kay D},
  title = {ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2024},
  doi = {10.1167/iovs.65.8.17}
}
Start for free →